Induced proximity beyond degradation at TPD Summit 2026

Oct 26–29, 2026 Boston, MA ~300 attendees Website

9 organizations at TPD Summit 2026 present work in induced proximity beyond degradation: 6 drug developers, 2 academic, government and non-profit bodies and 1 technology or service provider. Between them they bring 17 presentations to the program. Most represented: Amgen (2 on the program), Yale University (2 on the program), Concarlo Therapeutics (1 on the program). As of Oct 20, 2026.

All 96 organizations at TPD Summit 2026 →

Format
Top represented
Showing 1–9 of 9 organizations
OrganizationTPD Summit 2026 Attendance
Amgen
Thousand Oaks, CA
Large pharma
Global biopharmaceutical company with medicines in oncology, inflammation, cardiovascular and bone disease, and induced proximity research.
Chair
Wed Oct 28
8:20am
Part of Accelerating Induced Proximity Innovation Through Strategic Partnerships, Investment & Data-Driven Decision Making to Power the Future of Drug Development
Chair’s Opening Remarks
Plenary
Investment, partnering & strategy
Talk
Wed Oct 28
9:30am
Beyond Degraders: Are We Asking the Wrong Questions in Induced Proximity?
Plenary
Induced proximity beyond degradation
Panel
Wed Oct 28
10:00am
Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding
Plenary · with Flagship Pioneering, Novartis, Nurix Therapeutics +3 more
Investment, partnering & strategy
Talk
Thu Oct 29
2:15pm
GlueScope: Accelerating Molecular Glue Discovery through Orthogonal Proteomics & Deep Screening
Latest Tools & Technologies Track
Screening, assays & proteomics
Yale University
New Haven, CT
Academic & research
Private research university in New Haven, Connecticut, with a school of medicine.
Talk
Mon Oct 26
1:45pm
Enhancing Inhibition via Chemically Induced Proximity: A RIPTAC Targeting BCL6 & BET Proteins
Research Breakthroughs Day
Induced proximity beyond degradation
Panel
Mon Oct 26
2:15pm
Shaping the Future of Induced Proximity Research to Drive Innovative Discovery & Support the Development of Pipeline-Ready Candidates
Research Breakthroughs Day · with Janus Drug Discovery Consulting, Broad Institute, Albert Einstein College of Medicine +1 more
Degrader discovery & design
Biotech
Develops cancer therapeutics built on p27 biology, including molecular glue stabilizers, for drug-resistant cancers.
Panel
Tue Oct 27
3:10pm
Harnessing Rational Design and Structural Insights to Develop Induced Proximity Molecules with Enhanced Translational Potential
Track B: Pre-Clinical Development · with Protai, Biogen, Lyterian Therapeutics +1 more
Degrader discovery & design
Talk
Thu Oct 29
12:15pm
Locktacs for Intrinsically Disordered Proteins: First-in-Class p27 Molecular Glue Stabilizers
Future of Induced Proximity Track
Induced proximity beyond degradation
Academic & research
Medical school and biomedical research institution in the Bronx, New York.
Talk
Mon Oct 26
9:30am
αC-Helix–Proximal Allostery as a Platform for Selective Kinase Modulation & Complex Degradation
Research Breakthroughs Day
Degrader discovery & designInduced proximity beyond degradation
Panel
Mon Oct 26
2:15pm
Shaping the Future of Induced Proximity Research to Drive Innovative Discovery & Support the Development of Pipeline-Ready Candidates
Research Breakthroughs Day · with Janus Drug Discovery Consulting, Broad Institute, Yale University +1 more
Degrader discovery & design
Biotech
Develops targeted protein stabilization therapeutics that recruit deubiquitinases to rescue proteins rather than degrade them.
Panel
Tue Oct 27
9:00am
Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact
Plenary · with Nurix Therapeutics, Foghorn Therapeutics, C4 Therapeutics +1 more
Investment, partnering & strategy
Talk
Wed Oct 28
2:00pm
The Journey to DUBTAC Clinical Candidates
Track B: Pre-Clinical Development
Induced proximity beyond degradation
ICE Bioscience
Beijing, China
◇Program Partner
CROs & CDMOsProgram Partner
Integrated drug discovery CRO with biology, DMPK and translational platforms taking programs from target identification to preclinical candidate.
Talk
Tue Oct 27
3:10pm
Decoding RIPTAC Mechanism of Action: Deep Data Mining & Target-Effector Pair Differentiation in Novel Proximity-Based Therapeutics
Track A: Discovery
Induced proximity beyond degradation
Biotech
Develops monovalent molecular glue inhibitors and protein degraders from its TrueGlue discovery platform.
Talk
Wed Oct 28
12:30pm
Magnet Biomedicine’s TrueGlueTM Platform: A Systematic Approach Towards the Discovery of Molecular Glue Inhibitors (MGIs) for Therapeutic Tntervention
Track B: Pre-Clinical Development
Degrader discovery & designInduced proximity beyond degradation
Biotech
Neuroscience biotech designing brain-selective medicines for neurological diseases to improve safety and efficacy.
Talk
Thu Oct 29
11:45am
BrainTACs Enable Brain-Selective Inhibition of CNS Targets, with Reduced Peripheral Adverse Effects
Future of Induced Proximity Track
Induced proximity beyond degradationDegrader conjugates & tissue targeting
Revolution Medicines
Redwood City, CA
Biotech
Oncology company developing oral RAS(ON) inhibitors for RAS-driven cancers.
Talk
Wed Oct 28
8:30am
Tri-Complex Molecular Glues: RAS(ON) & Beyond
Plenary
Induced proximity beyond degradation

Explore the full TPD Summit 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full TPD Summit 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers in induced proximity beyond degradation

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Browse TPD Summit 2026 by

Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction